Previous 10 | Next 10 |
Reata Pharmaceuticals, Inc. (RETA) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Vineet Jindal - VP, Corporate Communications & Strategy Colin Meyer - Chief Medical Officer & EVP, Product Development Manmeet Soni - CFO & EVP Warren Huf...
Reata Pharmaceuticals (NASDAQ: RETA ): Q1 Non-GAAP EPS of -$0.89; GAAP EPS of -$1.47 beats by $0.52 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PLANO, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020, and prov...
PLANO, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on May 11, 2020. R...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Outperform rating and $54 (88% upside) price target at BMO. More news on: Apellis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Citing the impact of the COVID-19 pandemic, Reata Pharmaceuticals (NASDAQ: RETA ) has decided to halt the Phase 3 CATALYST study evaluating bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). It is also closing RANGER , the...
ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS SECOND YEAR OF PHASE 3 CARDINAL TRIAL CONTINUING AS PLANNED ENROLLMENT OF NEW PATIENTS IN FALCON TRIAL TEMPORARILY PAUSED PLANO, Texas, March 30, 2020 (G...
Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q4 2019 Earnings Call Feb 19, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...